Literature DB >> 24631835

Atomic basis of CRM1-cargo recognition, release and inhibition.

Ho Yee Joyce Fung1, Yuh Min Chook2.   

Abstract

CRM1 or XPO1 is the major nuclear export receptor in the cell, which controls the nuclear-cytoplasmic localization of many proteins and RNAs. CRM1 is also a promising cancer drug target as the transport receptor is overexpressed in many cancers where some of its cargos are misregulated and mislocalized to the cytoplasm. Atomic level understanding of CRM1 function has greatly facilitated recent drug discovery and development of CRM1 inhibitors to target a variety of malignancies. Numerous atomic resolution CRM1 structures are now available, explaining how the exporter recognizes nuclear export signals in its cargos, how RanGTP and cargo bind with positive cooperativity, how RanBP1 causes release of export cargos in the cytoplasm and how diverse inhibitors such as Leptomycin B and the new KPT-SINE compounds block nuclear export. This review summarizes structure-function studies that explain CRM1-cargo recognition, release and inhibition. Published by Elsevier Ltd.

Entities:  

Keywords:  Exportin; Karyopherin; NES; Nuclear export; Nuclear pore complex

Mesh:

Substances:

Year:  2014        PMID: 24631835      PMCID: PMC4108548          DOI: 10.1016/j.semcancer.2014.03.002

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  135 in total

Review 1.  Importins and exportins: how to get in and out of the nucleus.

Authors:  K Weis
Journal:  Trends Biochem Sci       Date:  1998-05       Impact factor: 13.807

2.  HEAT repeats in the Huntington's disease protein.

Authors:  M A Andrade; P Bork
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

3.  RanGAP1 induces GTPase activity of nuclear Ras-related Ran.

Authors:  F R Bischoff; C Klebe; J Kretschmer; A Wittinghofer; H Ponstingl
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

4.  Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.

Authors:  Qingxiang Sun; Yazmin P Carrasco; Youcai Hu; Xiaofeng Guo; Hamid Mirzaei; John Macmillan; Yuh Min Chook
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

5.  CRM1-mediated nuclear export: to the pore and beyond.

Authors:  Saskia Hutten; Ralph H Kehlenbach
Journal:  Trends Cell Biol       Date:  2007-02-20       Impact factor: 20.808

6.  Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

Authors:  Aiguo Shen; Yuchan Wang; Yueming Zhao; Lin Zou; Linlin Sun; Chun Cheng
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

7.  The role of exportin-t in selective nuclear export of mature tRNAs.

Authors:  G J Arts; S Kuersten; P Romby; B Ehresmann; I W Mattaj
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

8.  Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export.

Authors:  Rafael Bernad; Hella van der Velde; Maarten Fornerod; Helen Pickersgill
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

9.  Evolution of the karyopherin-β family of nucleocytoplasmic transport factors; ancient origins and continued specialization.

Authors:  Amanda J O'Reilly; Joel B Dacks; Mark C Field
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

10.  Structure of RCC1 chromatin factor bound to the nucleosome core particle.

Authors:  Ravindra D Makde; Joseph R England; Hemant P Yennawar; Song Tan
Journal:  Nature       Date:  2010-08-25       Impact factor: 49.962

View more
  50 in total

Review 1.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Nucleocytoplasmic Shuttling of the Mechanosensitive Transcription Factors MRTF and YAP /TAZ.

Authors:  Michael Kofler; András Kapus
Journal:  Methods Mol Biol       Date:  2021

3.  LocNES: a computational tool for locating classical NESs in CRM1 cargo proteins.

Authors:  Darui Xu; Kara Marquis; Jimin Pei; Szu-Chin Fu; Tolga Cağatay; Nick V Grishin; Yuh Min Chook
Journal:  Bioinformatics       Date:  2014-12-15       Impact factor: 6.937

4.  A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K.

Authors:  Iraia García-Santisteban; Igor Arregi; Marián Alonso-Mariño; María A Urbaneja; Juan J Garcia-Vallejo; Sonia Bañuelos; Jose A Rodríguez
Journal:  Cell Mol Life Sci       Date:  2016-06-16       Impact factor: 9.261

5.  Engineering chromosome region maintenance 1 fragments that bind to nuclear export signals.

Authors:  Yuqin Lei; Qi An; Yuqing Zhang; Ping Luo; Youfu Luo; Xiaofei Shen; Da Jia; Qingxiang Sun
Journal:  Protein Sci       Date:  2019-09-14       Impact factor: 6.725

6.  A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Authors:  Ramiro Garzon; Michael Savona; Rachid Baz; Michael Andreeff; Nashat Gabrail; Martin Gutierrez; Lynn Savoie; Paul Morten Mau-Sorensen; Nina Wagner-Johnston; Karen Yee; Thaddeus J Unger; Jean-Richard Saint-Martin; Robert Carlson; Tami Rashal; Trinayan Kashyap; Boris Klebanov; Sharon Shacham; Michael Kauffman; Richard Stone
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

7.  Ranbp1, Deleted in DiGeorge/22q11.2 Deletion Syndrome, is a Microcephaly Gene That Selectively Disrupts Layer 2/3 Cortical Projection Neuron Generation.

Authors:  Elizabeth M Paronett; Daniel W Meechan; Beverly A Karpinski; Anthony-Samuel LaMantia; Thomas M Maynard
Journal:  Cereb Cortex       Date:  2014-12-01       Impact factor: 5.357

8.  Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.

Authors:  Bhavana Bhatnagar; Qiuhong Zhao; Alice S Mims; Sumithira Vasu; Gregory K Behbehani; Karilyn Larkin; James S Blachly; William Blum; Rebecca B Klisovic; Amy S Ruppert; Shelley Orwick; Christopher Oakes; Parvathi Ranganathan; John C Byrd; Alison R Walker; Ramiro Garzon
Journal:  Leuk Lymphoma       Date:  2019-09-23

9.  Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.

Authors:  Mrinal M Gounder; Alona Zer; William D Tap; Samer Salah; Mark A Dickson; Abha A Gupta; Mary Louise Keohan; Herbert H Loong; Sandra P D'Angelo; Stephanie Baker; Mercedes Condy; Kjirsten Nyquist-Schultz; Lanier Tanner; Joseph P Erinjeri; Francis H Jasmine; Sharon Friedlander; Robert Carlson; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Joel Ellis; Michael Kauffman; Sharon Shacham; Gary K Schwartz; Albiruni Ryan Abdul Razak
Journal:  J Clin Oncol       Date:  2016-07-25       Impact factor: 44.544

10.  Karyopherin-β2 Recognition of a PY-NLS Variant that Lacks the Proline-Tyrosine Motif.

Authors:  Michael Soniat; Yuh Min Chook
Journal:  Structure       Date:  2016-09-08       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.